3Bonadonna G,Brusamolion E,Valagussa P,et al.Combination chemotherapy as an adjuvant treatment in operable breast cancer[J].N Engl J Med,1976,294:405 -410.
4Bonadonna G,Moliterni A,Zambetti M,et al.30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer[J].cohort study.BMJ,2005,330:217 -220
5Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21 (6):976 -983.
6Mamounas EP,Bryant J,Lembersky BC,et al.paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer.Results from NSABP B-28[J].Proc Am Soc Clin Oncol,2003,22:12A(Abstr 12).
7Jean-Marc Nabholtz,Tadeuz Pienkowski,John Mackey,et al.Phase Ⅲ trial comparing TAC (docetaxel,doxorubicin,cyclophsphamide) with FAC (5-fluorouracil,doxorubicin,cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients:interim analysis of the BCIRG 001 study[J].Proc Am Soc Clin Oncol,2002,21:36a (Abstr 141).
10ATAC Trialists' Group.Results of the ATAC (Arimidex,Tamoxifen,Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer[J].Lancet,2005,365(9453):60 -62.
二级参考文献16
1Bonadonna G, Valagussa PM,Olitemi A, et al. Adjuvant cyclophoshamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up [ J ]. N Engl J Med, 1995,332 ( 14 ) :901-906.
2Bonadonna G, Brusamolion E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer[ J]. N Engl J Med, 1976,294( 8 ) :405-410.
3Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study [ J ]. Br Med J, 2005,330 ( 7485 ): 217 -220.
4Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 [ J ]. J Clin Oncol,1990,8 ( 9 ): 1483-1496.
5Early Breast Cancer Trialist' s Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials [ J ]. Lancet, 1998,352 ( 9132 ) :930-932.
6Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patients and a natural history follow-up study in low risk node negative patients: first results of Intergroup trial in 0102 [ J ]. Proc Am Soc Clin Oncol , 1998,17: Abst 2.
7Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[ J]. J Clin Oncol,2003,21(6) :976-983.
8Mamounas EP, Bryant J, Lembersky BC, et al. paclitaxel (T)following doxorubicin/cyclophosphamide ( AC ) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 [ J ]. Proc Am Soc Clin Oncol,2003,22:12A ( Abstr12).
9Nabholtz JM,Pienkowski T, Mackey J, et al. Phase Ⅲ trial comparing TAC (docetaxel, doxorubicin, cyclophsphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer ( BC ) patients:interim analysis of the BCIRG 001 study[J]. Proc Am Soc Clin Oncol,2002,21:36a ( Abstr 141 ).
10Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer; first report of intergroup trail C9741/Cancer and leukemia Group B trial 9741[ J]. J Clin Onco1,2003,21 ( 8 ) :1431-1439.
7Bonadonna G, Brusamolion E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 1976, 294:405-410.
8Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 2005, 330:217-220.
9Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer. An overview of the randomized trials.Lancet, 1998, 352(9132) :930-932.
10Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomided trials. Lancet, 1998,351 : 1451-1467.
